Ketamine for the treatment of depression with anorexia nervosa

This randomised, double-blind, placebo-controlled Phase II trial (n=60) will study the feasibility, safety, and acceptability of oral ketamine (60–180mg, administered twice weekly) as a treatment for adults with long-standing anorexia nervosa and comorbid treatment-resistant depression.

Run by King’s College London and funded by the UK’s Medical Research Council, this study—called the EDEN project—aims to explore whether ketamine can improve depressive symptoms and recovery motivation in individuals with severe, enduring anorexia.

Participants must be aged 18 or older, have had anorexia nervosa for at least three years, and be currently experiencing depression that has not improved with at least one standard treatment. Over a six-month period, participants will attend 13 sessions, including eight in-person dosing sessions where they will receive either ketamine (using the KET-IR immediate-release capsule) or placebo in doses increasing from 60mg to a maximum of 180mg, based on tolerability. Outcomes will assess feasibility metrics (such as recruitment and retention), side effects, and exploratory changes in mood, eating disorder symptoms, and quality of life. The trial begins recruiting in August 2025 and will continue through April 2027.

Topic Eating Disorders Depression
Compound Ketamine Placebo
Country United Kingdom
Visit trial

Trial Details



Trial Number

Sponsors & Collaborators

King's College London
The Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King's College London is one of Europe's top centres for mental health and related neurosciences research.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.